Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma

OncoImmunology

Volumn 6, Issue 7, 2017, Pages

  Kikuchi, Masahiro ^a,b   Clump, David A ^b   Srivastava, Raghvendra M ^b   Sun, Lingyi ^b   Zeng, Dexing ^b   Diaz Perez, Julio A ^b,c   Anderson, Carolyn J ^b,d   Edwards, W Barry ^b   Ferris, Robert L ^b,e  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Translational Medicine Program   (Spain)

^d University of Pittsburgh   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Head and neck cancer; melanoma; PD L1; PET imaging; radiation

Indexed keywords

MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZIRCONIUM 89;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CANCER; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY CELL; ISOTOPE LABELING; MELANOMA; MICROVASCULATURE; MOUSE; NONHUMAN; PET-CT SCANNER; PROTEIN EXPRESSION; RADIATION DOSE; SIZE EXCLUSION CHROMATOGRAPHY; THIN LAYER CHROMATOGRAPHY; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 85021139903     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1329071     Document Type: Article

References (35)

1. Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375:1856-67; PMID:27718784; https://doi.org/10.1056/NEJMoa1602252
2. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; https://doi.org/10.1056/NEJMoa1302369
3. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74:5458-68; PMID:25274032; https://doi.org/10.1158/0008-5472.CAN-14-1258
4. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95; PMID:24382348; https://doi.org/10.1172/JCI67313
5. Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, et al. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 2017; 9, 167–80; PMID:27932443; https://doi.org/10.15252/emmm.201606674.
6. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances:A potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27:147-53; PMID:26483045; https://doi.org/10.1093/annonc/mdv489
7. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016; 2:46-54; PMID:26562159; https://doi.org/10.1001/jamaoncol.2015.3638
8. Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 2016; 27:1953-8; PMID:27502709; https://doi.org/10.1093/annonc/mdw289
9. Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, Yang Y, Huang Y, Zhao H, Zhang L. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 2016; 6:20090; PMID:26822379; https://doi.org/10.1038/srep20090 10.1038/srep23850
10. Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, et al. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. Eur J Cancer 2016; 52:1-9; PMID:26623522; https://doi.org/10.1016/j.ejca.2015.09.019
11. Hettich M, Braun F, Bartholoma MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 2016; 6:1629-40; PMID:27446497; https://doi.org/10.7150/thno.15253
12. Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S. PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET. Bioconjug Chem 2016; 27:2103-10; PMID:27458027; https://doi.org/10.1021/acs.bioconjchem.6b00348
13. Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 2015; 112:E6506-14; PMID:26604307; https://doi.org/10.1073/pnas.1519623112
14. Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochem Biophys Res Commun 2017; 483:258-63; PMID:28025143; https://doi.org/10.1016/j.bbrc.2016.12.156
15. McCabe KE, Wu AM. Positive progress in immunoPET—not just a coincidence. Cancer Biother Radiopharm 2010; 25:253-61; PMID:20578830; https://doi.org/10.1089/cbr.2010.0776
16. Hoover AC, Spanos WC, Harris GF, Anderson ME, Klingelhutz AJ, Lee JH. The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium. Arch Otolaryngol Head Neck 2007; 133:495-502; PMID:17515506; https://doi.org/10.1001/archotol.133.5.495
17. Zeng D, Guo Y, White AG, Cai Z, Modi J, Ferdani R, Anderson CJ. Comparison of conjugation strategies of cross-bridged macrocyclic chelators with cetuximab for copper-64 radiolabeling and PET imaging of EGFR in colorectal tumor-bearing mice. Mol Pharm 2014; 11:3980-7; PMID:24720806; https://doi.org/10.1021/mp500004m
18. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents:Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984; 142:68-78; PMID:6440451; https://doi.org/10.1016/0003-2697(84)90517-7
19. Lindmo T, Bunn PA, Jr. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 1986; 121:678-91; PMID:3523136
20. Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015; 75:508-18; PMID:25480946; https://doi.org/10.1158/0008-5472.CAN-14-1215
21. Schmitt NC, Trivedi S, Ferris RL. STAT1 activation is enhanced by cisplatin and variably affected by EGFR inhibition in HNSCC cells. Mol Cancer Ther 2015; 14:2103-11; PMID:26141950; https://doi.org/10.1158/1535-7163.MCT-15-0305
22. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:A potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; https://doi.org/10.1038/nm0902-1039c
23. Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, Barcellos-Hoff MH, Demaria S. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 2015; 75:2232-42; PMID:25858148; https://doi.org/10.1158/0008-5472.CAN-14-3511
24. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation:Relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155:172-82; PMID:15342209; https://doi.org/10.1016/j.jneuroim.2004.06.013
25. Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, Ritz J. Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015; 4:e1008824; PMID:26155422; https://doi.org/10.1080/2162402X.2015.1008824
26. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008; 180:3132-9; PMID:18292536; https://doi.org/10.4049/jimmunol.180.5.3132
27. Shahabi V, Postow MA, Tuck D, Wolchok JD. Immune-priming of the tumor microenvironment by radiotherapy:Rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clinical Oncol 2015; 38:90-7; PMID:25616204; https://doi.org/10.1097/COC.0b013e3182868ec8
28. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011; 71:2488-96; PMID:21300764; https://doi.org/10.1158/0008-5472.CAN-10-2820
29. Heskamp S, Hobo W, Molkenboer-Kuenen JDM, Olive D, Oyen WJG, Dolstra H, Boerman OC. Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti-PD-L1 antibodies. Cancer Res 2015; 75:2928-36; PMID:25977331; https://doi.org/10.1158/0008-5472.CAN-14-3477
30. Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, Azad BB, Pomper MG, Nimmagadda S. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 2016; 7:10215-27; PMID:26848870; https://doi.org/10.18632/oncotarget.7143
31. Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 2016; 6:1629; PMID:27446497; https://doi.org/10.7150/thno.15253
32. Josefsson A, Nedrow JR, Park S, Banerjee SR, Rittenbach A, Jammes F, Tsui B, Sgouros G. Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer. Cancer Res 2016; 76:472-9; PMID:26554829; https://doi.org/10.1158/0008-5472.CAN-15-2141
33. Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S. PD-L1 detection in tumors using [64Cu] atezolizumab with PET. Bioconjug Chem 2016; 27:2103-10; PMID:27458027; https://doi.org/10.1021/acs.bioconjchem.6b00348
34. Potchen EJ, Kinzie J, Curtis C, Siegel BA, Studer RK. Effect of irradiation on tumor microvascular permeability to macromolecules. Cancer 1972; 30:639-43; PMID:4677852; https://doi.org/10.1002/1097-0142(197209)30:3%3c639::AID-CNCR2820300308%3e3.0.CO;2-3
35. Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, Mitchell JB, et al. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004; 10:7712-20; PMID:15570005; https://doi.org/10.1158/1078-0432.CCR-04-1175